Pacira Up on Narrower-than-Expected Loss, Revenue Beat in Q2 - Analyst Blog

By
A A A

Pacira Pharmaceuticals, Inc. 's ( PCRX ) shares have been inching up since the company reported a narrower-than-expected loss for the second quarter of 2014. Shares, which were up 4.7% immediately after the release of second-quarter results, increased another 4.3% in the following trading session. Overall, shares were up 9.2%.

Pacira's second-quarter 2014 loss of 14 cents per share was well below the Zacks Consensus Estimate of a loss of 24 cents and the year-ago loss of 42 cents per share.

Second-quarter revenues soared 175.2% year over year to $47.2 million, surpassing the Zacks Consensus Estimate of $42 million. This increase in revenues is primarily due to higher demand.

The Quarter in Detail

Pacira's net revenues comprise product revenues, collaborative licensing and development revenues and royalty revenues. Exparel revenues were $44.9 million, up 195.4% from the year-ago quarter, primarily driven by higher demand for the drug. Collaboration and license agreement revenues and royalty revenues were $0.3 million (up 32.5%) and $0.8 million (up 30.5%), respectively.

Research and development (R&D) expenses increased 7.4% to $5.2 million from the year-ago quarter. Selling, general and administrative expenses increased 76.4% year over year to $24.8 million.

Till date, 2815 customers ordered Exparel since its launch, with 469 customers each ordering the product worth more than $100,000. In the reported quarter, Pacira gained 363 new customers who ordered Exparel. The company reported an average of 28 new accounts per week in the reported quarter.

Meanwhile, Pacira is working on the label expansion of Exparel. The company is currently seeking FDA approval for Exparel for femoral nerve-block in total knee arthroplasty with a response due by Mar 5, 2015.

Our Take

We are encouraged by Exparel's performance and pleased with Pacira's efforts to expands the product's label. Exparel should continue exhibiting strong growth. Meanwhile, we expect 2015 to be a catalyst rich year for Pacira as the company has an important regulatory event in Mar 2015 and also intends to file an investigational new drug application for one of its candidates in that year.

Pacira carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are Actelion Ltd. ( ALIOF ), Enzo Biochem Inc. ( ENZ ) and Endocyte, Inc. ( ECYT ). All these stocks sport a Zacks Rank #1 (Strong Buy).



Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ACTELION LTD (ALIOF): Get Free Report

ENZO BIOCHEM (ENZ): Get Free Report

ENDOCYTE INC (ECYT): Free Stock Analysis Report

PACIRA PHARMACT (PCRX): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.




This article appears in: Investing , Business , Stocks

Referenced Stocks: ALIOF , ENZ , ECYT , PCRX

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

75,427,639
  • $56.25 ▼ 1.58%
59,508,841
  • $16.67 ▼ 0.42%
47,696,026
  • $24.66 ▼ 0.64%
37,965,797
  • $3.80 ▼ 2.56%
29,288,629
  • $8 ▲ 0.25%
28,960,650
  • $131.78 ▼ 0.20%
26,875,249
  • $18.27 ▲ 1.56%
26,002,126
  • $34.01 ▲ 0.89%
As of 5/28/2015, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com